

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/706,567	11/12/2003	James L. Sackrison	DIA1001US	6918
9561	7590 11/02/2005	•	EXAMINER	
	, WILES & O'CONNI	VENCI, DAVID J		
650 THIRD AVENUE SOUTH SUITE 600 MINNEAPOLIS, MN 55402			ART UNIT	PAPER NUMBER
			1641	
			DATE MAILED: 11/02/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/706,567	SACKRISON ET AL.		
Examiner	Art Unit		
David J. Venci	1641	÷.	

	David J. Venci	1641	· .			
The MAILING DATE of this communication appe	ars on the cover sheet with the	correspondence add	ress			
THE REPLY FILED September 7, 2005 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.						
<ol> <li>The reply was filed after a final rejection, but prior to or of this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a N (3) a Request for Continued Examination (RCE) in comparing time periods:</li> </ol>	owing replies: (1) an amendment, a otice of Appeal (with appeal fee) in liance with 37 CFR 1.114. The rep	iffidavit, or other evid compliance with 37 (	ence, which CFR 41.31; or			
a) $\square$ The period for reply expires $3$ months from the mailing date of	·					
b) The period for reply expires on: (1) the mailing date of this Adverse, will the statutory period for reply expire later the	an SIX MONTHS from the mailing date o	f the final rejection.				
Examiner Note: If box 1 is checked, check either box (a) or (b) MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f	).					
Extensions of time may be obtained under 37 CFR 1.136(a). The date on been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened stabove, if checked. Any reply received by the Office later than three month earned patent term adjustment. See 37 CFR 1.704(b).  NOTICE OF APPEAL	and the corresponding amount of the fee. atutory period for reply originally set in the	The appropriate extension final Office action; or (2)	on fee under 37 as set forth in (b)			
2. The Notice of Appeal was filed on <u>September 7, 2005</u> . A of the date of filing the Notice of Appeal (37 CFR 41.37(a appeal. Since a Notice of Appeal has been filed, any repart to the AMENDMENTS	a)), or any extension thereof (37 CF	R 41.37(e)), to avoid	I dismissal of the			
3. The proposed amendment(s) filed after a final rejection,	but prior to the date of filing a brie	of will not be entered	hecause			
(a) ☐ They raise new issues that would require further co			because			
(b) They raise the issue of new matter (see NOTE belo		, ,				
(c) They are not deemed to place the application in be appeal; and/or		educing or simplifying	the issues for			
(d) ☐ They present additional claims without canceling a	corresponding number of finally re	ejected claims.				
NOTE: See Continuation Sheet. (See 37 CFR 1.	16 and 41.33(a)).	•				
4. The amendments are not in compliance with 37 CFR 1.	121. See attached Notice of Non-C	ompliant Amendmen	t (PTOL-324).			
5. Applicant's reply has overcome the following rejection(s):						
6. Newly proposed or amended claim(s) would be a the non-allowable claim(s).		e, timely filed amendn	nent canceling			
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proof The status of the claim(s) is (or will be) as follows:		vill be entered and an	explanation of			
Claim(s) allowed: <u>none</u> .			-			
Claim(s) objected to: <u>none</u> . Claim(s) rejected: <u>1-9 and 11-14</u> .						
Claim(s) rejected. <u>1-9 and 11-14.</u> Claim(s) withdrawn from consideration: <u>none</u> .						
AFFIDAVIT OR OTHER EVIDENCE						
8. The affidavit or other evidence filed after a final action, b because applicant failed to provide a showing of good ar and was not earlier presented. See 37 CFR 1.116(e).						
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessal.	overcome <u>all</u> rejections under appe	eal and/or appellant fa	ails to provide a			
10. The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	on of the status of the claims after	entry is below or atta	ched.			
	ut does NOT place the application	in condition for allowa	ance because:			
<ul> <li>11. ☑ The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet.</li> <li>12. ☐ Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s). ☐</li> <li>13. ☐ Other: ☐ LONG V. LE CALS OF SUPERVISORY PATENT EXAMINER</li> <li>TENSO OF CENTER 1600</li> </ul>						
10. [] Other		LONG V. LE	who/os			
	SUP T	FRVISORY PATENT E ECNICO DON CENTES	EXAMINER R 1600			

U.S. Patent and Trademark Office

## Continuation Sheet (PTOL-303)

Application No.

Continuation of 3: Applicants' amendment raises new issues that may require additional consideration and/or search. Specifically, claim 1 is amended to add the step of "contacting the sample with an antibody". Such a step limitation was not previously considered and may raise new issues under Sections 102, 103 and/or 112 of Title 35 USC.

Examiner posits that, in general, a step of "contacting the sample with an antibody" is not an inherent feature of all immunoassays. For example, an immunoassay may involve a sample comprising an antibody to assay said antibody. In such an immunoassay, a step of "contacting the sample with an antibody" is not required.

Continuation of 11: Applicants' amendment raises new issues that may require additional consideration and/or search. Specifically, claim 1 is amended to add the step of "contacting the sample with an antibody". Such a step limitation was not previously considered and may raise new issues under Sections 102, 103 and/or 112 of Title 35 USC.

Examiner posits that, in general, a step of "contacting the sample with an antibody" is not an inherent feature of all immunoassays. For example, an immunoassay may involve a sample comprising an antibody to assay said antibody. In such an immunoassay, a step of "contacting the sample with an antibody" is not required.